

## **Copy number alteration of neuropeptides and receptors in multiple cancers**

Min Zhao<sup>1§</sup>, Tianfang Wang<sup>1</sup>, Qi Liu<sup>2,3</sup>, Scott Cummins<sup>1§</sup>

<sup>1</sup>School of Engineering, Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Maroochydore DC, Queensland, 4558, Australia.

<sup>2</sup>Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.

<sup>3</sup>Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.

§ To whom correspondence should be addressed, [mzhao@usc.edu.au](mailto:mzhao@usc.edu.au), [scummins@usc.edu.au](mailto:scummins@usc.edu.au).

## **Supplement**

**Table S1.** Details of 127 human genes that encode neuropeptide precursors.


**Table S2.** Prognostic Z-scores of human neuropeptide across 23 cancer types.

**Table S3.** Interaction of 93 neuropeptides and 133 receptors.


**Table S4.** Co-mutated genes with SDC2 in neuroendocrine prostate cancer.

**Table S5.** Global feature of 118 genes from four functional modules.


**Figure S1.** Scatterplot about the cellular component (A) and molecular function (B) for 127 neuropeptides.



**Figure S2.** Mutational pattern of 44 genes in module 1 for CCLE dataset.



**Figure S3.** Mutational pattern of 44 genes in module 1 for pancreatic cancer.



**Figure S4.** Mutational pattern of 39 genes in module 2 for pancreatic cancer.

